Athira Pharma Inc Ordinary Shares ATHA
News
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
Athena Gold Announces Transformative Transaction With Libra To Create a Premier, Discovery Focused Gold Explorer in Nevada and Ontario, With Enhanced Board and Management Team and Plans to Redomicile to Canada
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
Athena Gold Corporation Completes Acquisition of the Historic Blue Dick Mine and Significantly Expands Its Flagship Excelsior Springs Gold Project in Nevada
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease